Rachel Haurwitz

From Wikipedia, the free encyclopedia

Rachel Haurwitz
Rachel Haurwitz 2019.jpg
Haurwitz in 2019
Born
Rachel Elizabeth Haurwitz

(1985-05-20) May 20, 1985 (age 36)
Austin, Texas, U.S.
Alma mater
Scientific career
FieldsBiochemistry
InstitutionsCaribou Biosciences
ThesisThe CRISPR endoribonuclease Csy4 utilizes unusual sequence- and structure-specific mechanisms to recognize and process crRNAs (2012)
Doctoral advisorJennifer Doudna
Other academic advisorsJillian Banfield

Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.

Early life and education[]

Haurwitz was born on May 20, 1985.[citation needed] She grew up in Austin, Texas. Her mother is an elementary school teacher and her father, an environmental journalist. [1]

Haurwitz began researching RNA during her undergraduate years.[2] She attended Harvard College where she earned an undergraduate degree. In 2007, she began doctoral studies at University of California, Berkeley. At the age of 21,[3] Haurwitz began working as a graduate student in Jennifer Doudna's laboratory, in 2008 where she completed her doctorate in molecular and cell biology.[4] Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue in science.[5]

Career[]

In 2011, Haurwitz and Doudna co-founded Caribou Biosciences, a gene editing spinout-startup company.[6] Haurwitz is the company's CEO and president. She holds several patents for CRISPR-based technologies.[4] The firm was initially housed in the basement of the building that housed Doudna's laboratory. The company supports the commercialization[7] of CRISPR technology in healthcare and agriculture.[8] Its researchers explore issues in antimicrobial resistance, food scarcity, and vaccine shortages.[8] The company licensed Berkeley's CRISPR patent and deals with agricultural and pharmaceutical companies and research firms.[9] In 2018, Haurwitz announced that the firm was shifting focus on medicine and developing cancer therapies targeting microbes.[1]

Personal life[]

She is a long-distance runner and is training for a marathon.[8] Haurwitz knits as a hobby.[5]

Selected works[]

Papers[]

  • Haurwitz, Rachel E.; Jinek, Martin; Wiedenheft, Blake; Zhou, Kaihong; Doudna, Jennifer A. (September 10, 2010). "Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease". Science. 329 (5997): 1355–1358. doi:10.1126/science.1192272. PMC 3133607. PMID 20829488.
  • Qi, Lei; Haurwitz, Rachel E; Shao, Wenjun; Doudna, Jennifer A; Arkin, Adam P (September 16, 2012). "RNA processing enables predictable programming of gene expression". Nature Biotechnology. 30 (10): 1002–1006. doi:10.1038/nbt.2355. PMID 22983090. S2CID 1333889.

References[]

  1. ^ Jump up to: a b Fosco, Molly (March 16, 2018). "This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer". OZY. Retrieved September 5, 2018.
  2. ^ Herman, Elizabeth D. (June 22, 2016). "For biotech CEO Rachel Haurwitz, CRISPR is big business". STAT. Retrieved September 5, 2018.
  3. ^ "The two faces of Rachel Haurwitz". MPNforum Magazine. April 9, 2015. Retrieved September 5, 2018.
  4. ^ Jump up to: a b Buhr, Sarah (September 4, 2018). "These two CRISPR experts are coming to Disrupt SF 2018". TechCrunch. Retrieved September 5, 2018.
  5. ^ Jump up to: a b "40 Under 40". Fortune. September 22, 2016. Retrieved September 5, 2018.
  6. ^ "Rachel Haurwitz". Forbes. Retrieved September 5, 2018.
  7. ^ Leeming, Jack (April 5, 2018). "How researchers are ensuring that their work has an impact". Nature. 556 (7699): 139–141. doi:10.1038/d41586-018-03925-8. ISSN 0028-0836. PMID 29620739.
  8. ^ Jump up to: a b c "NOMINEE: Rachel Haurwitz". Newsweek. January 18, 2018. Retrieved September 5, 2018.
  9. ^ Regalado, Antonio (2017). "One woman's ascent from lab rat to CEO of a CRISPR company". MIT Technology Review. Retrieved September 5, 2018.

External links[]

Retrieved from ""